**Note-taking template for Country Malaria vaccine mini-PIE (also known as, Intra-Action Review (IAR))**

**[COUNTRY]**

**Date(s) of mini-PIE facilitated discussion: [DD/MM/YYYY**]

*Instructions:*

* *This template will be used by the notetaker during the mini-PIE facilitated discussion.*
* *The table below should be duplicated, so one table can be completed for each vaccination programme pillar reviewed.*
* *In the table, the sections on “Best practices” and on “Challenges” should be completed during the session “STEP 1”. The section on “Recommended actions” should be completed during the session “STEP 2”.*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PILLAR :** | |  | | |
| **BEST PRACTICES** | | | **IMPACT(S)** | **ENABLING FACTORS** |
| 1. | *Best practice 1:* | | *Impact 1:*  *Impact 2:* | *Enabling factor 1:*  *Enabling factor 2:*  *Enabling factor 3:* |
| 2. | *Best practice 2:* | | *Impact 1:*  *Impact 2:* | *Enabling factor 1:*  *Enabling factor 2:*  *Enabling factor 3:* |
| 3. | *Best practice 3:* | | *Impact 1:*  *Impact 2:* | *Enabling factor 1:*  *Enabling factor 2:*  *Enabling factor 3:* |
| … | … | |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **CHALLENGES** | | **IMPACT(S)** | **LIMITING FACTORS** |
| 1. | *Challenge 1:* | *Impact 1:*  *Impact 2:* | *Limiting factor 1:*  *Limiting factor 2:*  *Limiting factor 3:* |
| 2. | *Challenge 2:* | *Impact 1:*  *Impact 2:* | *Limiting factor 1:*  *Limiting factor 2:*  *Limiting factor 3:* |
| 3. | *Challenge 3:* | *Impact 1:*  *Impact 2:* | *Limiting factor 1:*  *Limiting factor 2:*  *Limiting factor 3:* |
| … | … |  |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **RECOMMENDED ACTIONS** | | **DESIRED DATE FOR COMPLETION** | **RESPONSIBLE FOCAL POINT** | **REQUIRED SUPPORT** | **INDICATORS** |
| 1. For immediate implementation: | | | | | |
| 1. |  |  |  |  |  |
|  |  |
|  |  |
| 2. |  |  |  |  |  |
|  |  |
|  |  |
| 3. |  |  |  |  |  |
|  |  |
|  |  |
| … | … |  |  |  |  |
|  |  |
|  |  |
| 1. For mid to long-term implementation to improve ongoing malaria vaccine delivery: | | | | | |
| 1. |  |  |  |  |  |
|  |  |
|  |  |
| 2. |  |  |  |  |  |
|  |  |
|  |  |
| 3. |  |  |  |  |  |
|  |  |
|  |  |
| … |  |  |  |  |  |
|  |  |
|  |  |